Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)

Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01327222

Acronym

LOW-VISION

Enrollment

Registered

2011-04-01

Start date

2011-02-28

Completion date

2011-02-28

Last updated

2011-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Keywords

age-related macular degeneration, bevacizumab

Brief summary

The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.

Detailed description

There is no clear indication regarding the treatment of patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200. Treatment of eyes with low visual acuity could lead to a waste of resources, without any functional and social improvements. Aim of the present study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in

Interventions

DRUGBevacizumab

1.25 mg intravitreal bevacizumab

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

55 Years to 90 Years

Healthy volunteers

Inclusion criteria

* age-related macular degeneration * naïve subfoveal choroidal neovascularization * best-corrected visual acuity less then 20/200

Exclusion criteria

* previous treatments * any other condition able to limit the visual improvement

Design outcomes

Primary

Measure	Time frame	Description
change in best-corrected visual acuity	6 months	change in best-corrected visual acuity at the end of the follow-up

Secondary

Measure	Time frame	Description
change in central macular thickness	6 months	change in central macular thickness on OCT
NEI VFQ-25 scores	6 months	change in NEI VFQ-25 scores questionnaire

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026